
    
      OUTLINE: This is a multi-center study.

      Sorafenib 200mg po daily Bevacizumab 5mg/kg every other week

      1 Cycle = 4 weeks Imaging every third cycle

      Acceptable toxicity and non-PD = Protocol therapy will continue Un-acceptable toxicity or PD
      = Protocol therapy will be discontinued

      ECOG Performance Status 0-1

      Life Expectancy: at least 12 weeks

      Hematopoietic:

        -  Platelets > 100 K/mm3

        -  Absolute neutrophil count (ANC) > 1.5 K/mm3

        -  Hemoglobin > 10 g/dL

      Hepatic:

        -  Total Bilirubin < 1.5 x ULN

        -  Aspartate aminotransferase (AST, SGOT) < 2 x ULN (up to 5 x ULN in patients with known
           liver involvement)

      Renal:

        -  Creatinine < 1.5 x ULN

        -  No proteinuria as demonstrated by either Urine protein:creatinine (UPC) ratio < 1.0 or
           Urine dipstick for proteinuria < 2+

      Cardiovascular:

        -  No known myocardial infarction, unstable angina, > grade II New York Heart Association
           (NYHA) classification, congestive heart failure, uncontrolled hypertension defined as
           SBP >150 or DBP >100, > grade II peripheral vascular disease or significant vascular
           disease (e.g. aortic aneurysm, aortic dissection) within 12 months prior to being
           registered for protocol therapy.

        -  No uncontrolled or clinically significant arrhythmia. NOTE: Controlled atrial
           fibrillation is allowed.

        -  LVEF ≥ LLN by MUGA or ECHO as obtained within 28 days prior to being registered for
           protocol therapy.

      Pulmonary:

        -  No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within 28 days prior to being
           registered for protocol therapy.
    
  